<p>Immunic（纳斯达克股票代码：IMUX - 获取免费报告）在周五发布给客户和投资者的研究报告中，研究分析师 HC Wainwright 将其目标价格从 10.00 美元下调至 8.00 美元。该公司目前对该股票的评级为 “买入”。</p>
<p>其他几位股票分析师也最近对 IMUX 发表了看法。D. Boral Capital 在周四的报告中将 Immunic 的目标价格从 10.00 美元下调至 8.00 美元，并对该公司给予 “买入” 评级。Weiss Ratings 在 10 月 8 日（星期三）的报告中重申了对 Immunic 股票的 “卖出（d-）” 评级。Roth Capital 在 11 月 7 日（星期五）的报告中开始覆盖 Immunic，给予 “买入” 评级，并设定 3.00 美元的目标价格。LADENBURG THALM/SH SH 在 10 月 16 日（星期四）的研究报告中将 Immunic 的评级提升至 “强力买入”。最后，Chardan Capital 在 9 月 29 日（星期一）的研究报告中开始覆盖 Immunic，给予 “买入” 评级，并设定 13.00 美元的目标价格。一位研究分析师对该股票给予 “强力买入” 评级，六位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，Immunic 目前的共识评级为 “适度买入”，共识目标价格为 7.40 美元。</p>
<p><strong>查看我们对 Immunic 的最新股票分析</strong></p>
<h2>Immunic 价格表现</h2>
<p>IMUX 股票在周五的交易时段上涨 0.03 美元，达到 0.74 美元。该公司的交易量为 364,413 股，而其平均交易量为 1,285,254 股。该公司的市值为 7320 万美元，市盈率为-0.79，贝塔值为 1.53。Immunic 的 1 年最低价为 0.56 美元，1 年最高价为 1.42 美元。该公司的 50 日移动平均价为 0.83 美元，200 日移动平均价为 0.87 美元。</p>
<p>Immunic（纳斯达克股票代码：IMUX - 获取免费报告）最后一次公布财报是在 11 月 13 日（星期四）。该公司报告本季度每股收益（EPS）为-0.13 美元，超出市场共识预期的-0.18 美元，超出幅度为 0.05 美元。作为一个整体，卖方分析师预测 Immunic 在当前财政年度将发布-0.94 美元的每股收益。</p>
<h2>机构资金流入和流出</h2>
<p>一些大型投资者最近调整了对该股票的持有。阿伯丁集团（Aberdeen Group plc）在第一季度购买了 Immunic 的新头寸，价值 115.5 万美元。683 资本管理公司（683 Capital Management LLC）在第一季度将其在 Immunic 的持股增加了 28.6%。683 资本管理公司目前拥有 90 万股该公司的股票，价值 98.1 万美元，此前在上个季度购买了额外的 20 万股。简街集团（Jane Street Group LLC）在第一季度将其在 Immunic 的持仓增加了 279.3%。简街集团目前拥有 207,401 股该公司的股票，价值 22.6 万美元，此前在上个季度购买了额外的 152,726 股。Focus Partners Wealth 在第一季度将其在 Immunic 的股份增加了 19.1%。Focus Partners Wealth 目前拥有 2,583,457 股该公司的股票，价值 281.6 万美元，此前在上个季度购买了额外的 415,104 股。最后，HB Wealth Management LLC 在第三季度购买了 Immunic 的新头寸，价值约 81,000 美元。机构投资者持有该公司 51.82% 的股票。</p>
<h2>Immunic 公司简介</h2>
<p>（获取免费报告）</p>
<p>Immunic, Inc 是一家生物技术公司，开发一系列选择性口服免疫疗法，用于治疗美国和德国的慢性炎症和自身免疫性疾病。其主要开发项目是 IMU-838，目前正在进行第三阶段临床试验，旨在治疗多发性硬化症，包括复发性和进展性多发性硬化症；以及中度至重度溃疡性结肠炎。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票，胜过 Immunic</li>
<li>电动车股票及其盈利方式</li>
<li>LightPath 股票因国防需求激增而瞄准 50% 的上涨空间</li>
<li>如何知道一只股票是否支付股息以及何时支付</li>
<li>CRWD 股票在财报前达到关键拐点</li>
<li>为什么股票行业对成功投资如此重要？</li>
<li>Rigetti 的第三季度失利揭示了量子资金和时机压力</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1VWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1VWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Immunic 吗？</h2>
<p>在你考虑 Immunic 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Immunic 并不在名单上。</p>
<p>虽然 Immunic 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

IMUX

<p>HC Wainwright 将 Immunic（NASDAQ:IMUX）的目标价格从 10.00 美元下调至 8.00 美元，维持 “买入” 评级。其他分析师也调整了他们的评级，有些设定了更低的目标，有些则发布了 “买入” 评级。Immunic 的股票表现和机构投资者活动受到关注。该公司专注于开发慢性炎症和自身免疫疾病的治疗方案。最近的财报显示每股收益略微超出预期。该股票的共识评级为 “适度买入”，目标价格为 7.40 美元</p>

<p>Immunic (NASDAQ:IMUX - Get Free Report) had its target price dropped by research analysts at HC Wainwright from $10.00 to $8.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a &#34;buy&#34; rating on the stock.</p>
<div class="lb-trans"><p>Immunic（纳斯达克股票代码：IMUX - 获取免费报告）在周五发布给客户和投资者的研究报告中，研究分析师 HC Wainwright 将其目标价格从 10.00 美元下调至 8.00 美元。该公司目前对该股票的评级为 “买入”。</p>
</div><p>Several other equities analysts have also recently weighed in on IMUX. D. Boral Capital decreased their price objective on Immunic from $10.00 to $8.00 and set a &#34;buy&#34; rating for the company in a report on Thursday. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Immunic in a report on Wednesday, October 8th. Roth Capital started coverage on Immunic in a report on Friday, November 7th. They set a &#34;buy&#34; rating and a $3.00 target price on the stock. LADENBURG THALM/SH SH raised Immunic to a &#34;strong-buy&#34; rating in a research note on Thursday, October 16th. Finally, Chardan Capital started coverage on Immunic in a research note on Monday, September 29th. They issued a &#34;buy&#34; rating and a $13.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Immunic presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $7.40.</p>
<div class="lb-trans"><p>其他几位股票分析师也最近对 IMUX 发表了看法。D. Boral Capital 在周四的报告中将 Immunic 的目标价格从 10.00 美元下调至 8.00 美元，并对该公司给予 “买入” 评级。Weiss Ratings 在 10 月 8 日（星期三）的报告中重申了对 Immunic 股票的 “卖出（d-）” 评级。Roth Capital 在 11 月 7 日（星期五）的报告中开始覆盖 Immunic，给予 “买入” 评级，并设定 3.00 美元的目标价格。LADENBURG THALM/SH SH 在 10 月 16 日（星期四）的研究报告中将 Immunic 的评级提升至 “强力买入”。最后，Chardan Capital 在 9 月 29 日（星期一）的研究报告中开始覆盖 Immunic，给予 “买入” 评级，并设定 13.00 美元的目标价格。一位研究分析师对该股票给予 “强力买入” 评级，六位分析师给予 “买入” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，Immunic 目前的共识评级为 “适度买入”，共识目标价格为 7.40 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on Immunic</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Immunic 的最新股票分析</strong></p>
</div><h2>Immunic Price Performance</h2>
<div class="lb-trans"><h2>Immunic 价格表现</h2>
</div><p>Shares of IMUX stock traded up $0.03 during trading hours on Friday, reaching $0.74. The company had a trading volume of 364,413 shares, compared to its average volume of 1,285,254. The firm has a market cap of $73.20 million, a price-to-earnings ratio of -0.79 and a beta of 1.53. Immunic has a 1-year low of $0.56 and a 1-year high of $1.42. The company has a 50 day moving average of $0.83 and a 200 day moving average of $0.87.</p>
<div class="lb-trans"><p>IMUX 股票在周五的交易时段上涨 0.03 美元，达到 0.74 美元。该公司的交易量为 364,413 股，而其平均交易量为 1,285,254 股。该公司的市值为 7320 万美元，市盈率为-0.79，贝塔值为 1.53。Immunic 的 1 年最低价为 0.56 美元，1 年最高价为 1.42 美元。该公司的 50 日移动平均价为 0.83 美元，200 日移动平均价为 0.87 美元。</p>
</div><p>Immunic (NASDAQ:IMUX - Get Free Report) last announced its earnings results on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.05. As a group, sell-side analysts forecast that Immunic will post -0.94 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Immunic（纳斯达克股票代码：IMUX - 获取免费报告）最后一次公布财报是在 11 月 13 日（星期四）。该公司报告本季度每股收益（EPS）为-0.13 美元，超出市场共识预期的-0.18 美元，超出幅度为 0.05 美元。作为一个整体，卖方分析师预测 Immunic 在当前财政年度将发布-0.94 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of large investors have recently modified their holdings of the stock. Aberdeen Group plc bought a new position in Immunic during the 1st quarter valued at $1,155,000. 683 Capital Management LLC boosted its holdings in Immunic by 28.6% during the first quarter. 683 Capital Management LLC now owns 900,000 shares of the company's stock worth $981,000 after purchasing an additional 200,000 shares during the last quarter. Jane Street Group LLC grew its position in Immunic by 279.3% in the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock worth $226,000 after purchasing an additional 152,726 shares in the last quarter. Focus Partners Wealth increased its stake in Immunic by 19.1% in the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company's stock valued at $2,816,000 after buying an additional 415,104 shares during the last quarter. Finally, HB Wealth Management LLC bought a new position in shares of Immunic in the third quarter valued at approximately $81,000. Institutional investors own 51.82% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投资者最近调整了对该股票的持有。阿伯丁集团（Aberdeen Group plc）在第一季度购买了 Immunic 的新头寸，价值 115.5 万美元。683 资本管理公司（683 Capital Management LLC）在第一季度将其在 Immunic 的持股增加了 28.6%。683 资本管理公司目前拥有 90 万股该公司的股票，价值 98.1 万美元，此前在上个季度购买了额外的 20 万股。简街集团（Jane Street Group LLC）在第一季度将其在 Immunic 的持仓增加了 279.3%。简街集团目前拥有 207,401 股该公司的股票，价值 22.6 万美元，此前在上个季度购买了额外的 152,726 股。Focus Partners Wealth 在第一季度将其在 Immunic 的股份增加了 19.1%。Focus Partners Wealth 目前拥有 2,583,457 股该公司的股票，价值 281.6 万美元，此前在上个季度购买了额外的 415,104 股。最后，HB Wealth Management LLC 在第三季度购买了 Immunic 的新头寸，价值约 81,000 美元。机构投资者持有该公司 51.82% 的股票。</p>
</div><h2>Immunic Company Profile</h2>
<div class="lb-trans"><h2>Immunic 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.</p>
<div class="lb-trans"><p>Immunic, Inc 是一家生物技术公司，开发一系列选择性口服免疫疗法，用于治疗美国和德国的慢性炎症和自身免疫性疾病。其主要开发项目是 IMU-838，目前正在进行第三阶段临床试验，旨在治疗多发性硬化症，包括复发性和进展性多发性硬化症；以及中度至重度溃疡性结肠炎。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Immunic</li>
<li>EV Stocks and How to Profit from Them</li>
<li>LightPath Stock Eyes 50% Upside on Defense Demand Surge</li>
<li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li>
<li>CRWD Stock Hits Key Inflection Point Ahead of Earnings</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>Rigetti’s Q3 Miss Reveals Quantum Funding and Timing Pressures</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Immunic</li>
<li>电动车股票及其盈利方式</li>
<li>LightPath 股票因国防需求激增而瞄准 50% 的上涨空间</li>
<li>如何知道一只股票是否支付股息以及何时支付</li>
<li>CRWD 股票在财报前达到关键拐点</li>
<li>为什么股票行业对成功投资如此重要？</li>
<li>Rigetti 的第三季度失利揭示了量子资金和时机压力</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1VWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=IMUX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immunic Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Immunic 吗？</h2>
</div><p>Before you consider Immunic, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Immunic 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Immunic 并不在名单上。</p>
</div><p>While Immunic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Immunic 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 将 Immunic（NASDAQ:IMUX）的目标股价下调至 8.00 美元